Latest QIAGEN N.V. Stories
VENLO, The Netherlands, April 29, 2013 /PRNewswire/ -- - Achieves Q1 2013 targets: Net sales of $303.6 million grow 3% CER on expansion in all regions; adjusted diluted EPS at $0.23 per share; free cash flow of $30 million - Progress toward accelerating innovation and growth in 2013: - Molecular Diagnostics (+11% CER) and Applied Testing (+5% CER) deliver solid results, more than offset weak market...
MARCO ISLAND, Florida, and HILDEN, Germany, February 20, 2013 /PRNewswire/ -- - Streamlined and automated NGS workflow will offer many features required to enable routine use in clinical applications - Building on strengths in Sample & Assay Technologies to create an integrated NGS ecosystem with sample processing, genomic testing and bioinformatics - New consumable products address critical workflow challenges, expanding...
FREMONT, Calif., Feb. 19, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCBB: WGBS) announced today a co-marketing agreement with QIAGEN KK - a subsidiary of QIAGEN N.V.- for the joint promotion of certain products in Japan in the areas of genomics platforms such as Next-Gen sequencing (NGS) and qPCR. With the joint offering, customers will be able to seamlessly plan and execute complex research projects involving molecular biomarker discovery with NGS, where WaferGen's...
GERMANTOWN, Maryland and HILDEN, Germany, February 13, 2013 /PRNewswire/ -- - Arrangement to facilitate future collaborations in personalized medicine - Provides framework to develop and commercialize QIAGEN companion diagnostics paired with Lilly medicines in an effort to improve outcomes for individual patients - Builds on the two companies' recent mutual successes QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today...
HILDEN, Germany and GERMANTOWN, Maryland, January 30, 2013 /PRNewswire/ -- - Momentum builds for therascreen(R)KRAS RGQ PCR Kit and Rotor-Gene Q MDx instrument - Clarient offers network of 2,000-plus pathologists testing with therascreen KRAS RGQ PCR Kit, the only FDA-approved KRAS companion diagnostic for Erbitux(R)in metastatic colorectal cancer - KRAS launch prepares way for QIAGEN's growing pipeline of...
VENLO, The Netherlands, January 29, 2013 /PRNewswire/ -- - QIAGEN exceeds Q4 and full-year 2012 targets: - Full-year 2012: Net sales advance 10% CER (+7% reported) to $1.25 billion on growth in all customer classes and regions; adjusted diluted EPS at $1.08 per share - Q4 2012: Net sales rise 4% CER (+4% reported) to $346.5 million, year-ago results included major product tender; adjusted diluted EPS at $0.34 per share -...
HILDEN, Germany and GERMANTOWN, Maryland, January 15, 2013 /PRNewswire/ -- - U.S. submission of therascreen(R) EGFR RGQ PCR Kit is paired with FDA submission of afatinib, an investigational tyrosine kinase inhibitor developed by Boehringer Ingelheim - Companion diagnostic intended to aid treatment decisions in non-small cell lung cancer - QIAGEN continues to expand Personalized Healthcare portfolio and content menu...
HILDEN, Germany and GERMANTOWN, Maryland, January 7, 2013 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today that it exceeded its goal for new placements of the QIAsymphony modular laboratory workflow platform in 2012. The growth of QIAsymphony, which offers full workflow solutions from biological sample to result, reached well more than 750 placements at the end of 2012, building on more than 550 at the end of 2011. "We are very...
HILDEN, Germany and GERMANTOWN, Maryland, January 7, 2013 /PRNewswire/ -- - QIAGEN invests in new companion diagnostic being developed by Drug Response Dx that aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients - Rights to RET, ROS1 and DEPDC1 biomarkers gained from Insight Genetics offer promise as companion diagnostics in lung cancer - New tests from Inserm for mutations of HSP110 gene...
SHENZEN, China and HILDEN, Germany, November 28, 2012 /PRNewswire/ -- - Commercial launch of careHPV in China and other emerging markets will enable high-quality screening for prevention of cervical cancer - "Country of Origin" approval key for dissemination, other countries are able to use this as a basis for registration - careHPV is the first HPV test designed for areas with limited healthcare infrastructure,...
